Contents: virus tracking reports for all 50 states + DC

Chart 1: Infections vs hospitalizations
Chart 2: Daily deaths vs case fatality rates
Chart 3: Infections, hospitalizations and mortality
Chart 4: Deaths as a % of current hospitalizations
Chart 5: Daily number of tests and percentage of positive tests
Chart 6: Infections vs doctor visits with COVID-like symptoms
Chart 7: Hospital bed and ICU bed utilization rates vs 2018 averages

States appear in this report in descending order of State GDP.
Note that hospitalization data is available for all states with the exception of Hawaii and Kansas.

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.
**California virus tracking**

- New infections per mm, with % of positive cases
- Active hospitalizations per mm

**California virus tracking**

- Daily deaths per mm
- Case fatality rate, infections lagged 18 days

**California virus tracking**

- New daily infections (LHS)
- Current hospitalizations (LHS)
- Daily deaths (RHS)

**California virus tracking**

- Positive testing rate (LHS)
- Total daily tests (RHS)

**California virus tracking**

- Hospital bed utilization rate
- ICU bed utilization rate
- 2018 hospital bed utilization rate
- 2018 ICU bed utilization rate

Source: COVID Tracking Project, JPAM 9/1/2020. 7 day avgs.
Pennsylvania virus tracking
New infections per mm, with % of positive cases
Active hospitalizations per mm

Reopening

New infections per mm (LHS)
Cur Hosp (LHS)
Daily deaths (RHS)

Daily deaths as a % of current hospitalizations

Positive tests/total tests
Total daily tests (000's)

New daily infections (LHS)
Cur Hosp (LHS)
Daily deaths (RHS)

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Hospital bed utilization rate
ICU bed utilization rate
2018 hosp bed utilization rate
2018 ICU bed utilization rate

Hospital utilization rates

New Jersey virus tracking

- New infections per mm, with % of positive cases
- Active hospitalizations per mm
- Reopening
- New infections per mm, with % of positive cases
- Active hospitalizations per mm
- Reopening

New Jersey virus tracking

- New daily infections (LHS)
- Cur Hosp (LHS)
- Daily deaths (RHS)

New Jersey virus tracking

- Positive tests/total tests
- Total daily tests (000’s)

New Jersey virus tracking

- New daily infections per mm
- Percentage

New Jersey virus tracking

- Hospital utilization rates

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.
Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.
Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.
Washington virus tracking

Reopening
9%
8%
7%
6%
5%
4%
3%

Active hospitalizations per mm

Case fatality rate, infections lagged 18 days

Daily deaths as a % of current hospitalizations

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Positive tests/total tests

Total daily tests (000’s)

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Hospital utilization rates

Eye on the Market Coronavirus tracking: Louisiana

Michael Cembalest
JP Morgan

Reopening

30% 9% 17% 6% 6% 5% 5%

0% 5% 5% 5% 5% 5% 5% 5% 5%

0% 5% 5% 5% 5% 5% 5% 5% 5%

0% 5% 5% 5% 5% 5% 5% 5% 5%

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Alabama virus tracking

Current hospitalizations and daily infections

Daily deaths

Reopening

Case fatality rate, infections lagged 18 days

New daily infections (LHS)

Hospital utilization rates

Hospital bed utilization rate

ICU bed utilization rate

2018 hosp bed utilization rate

2018 ICU bed utilization rate

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.


Mississippi virus tracking

Current hospitalizations and daily infections

Daily deaths

New daily infections per mm, with % of positive cases

Active hospitalizations per mm

Reopening

Reopening

Mississippi virus tracking

Case fatality rate, infections lagged 18 days

Current hospitalizations and daily infections

Daily deaths as a % of current hospitalizations

Positive testing rate (LHS)

Total daily tests (000's)

New infections per mm (LHS)

% of doctor visits with COVID-like symptoms (RHS)

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.


Hospital utilization rates

Eye on the Market Coronavirus tracking: New Mexico

Michael Cembalest
JP Morgan

Reopening

2%
5%
6%
6%
5% 4% 2% 3% 3% ...

New Mexico virus tracking

Current hospitalizations and daily infections

Daily deaths

New Mexico virus tracking

Positive tests/total tests

Total daily tests (000's)

Hospital utilization rates

New Mexico virus tracking

Hospital bed utilization rate

ICU bed utilization rate

2018 hosp bed utilization rate

2018 ICU bed utilization rate

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.


New Mexico virus tracking

New daily infections per mm

Percentage


Hospital bed utilization rate

ICU bed utilization rate

2018 hosp bed utilization rate

2018 ICU bed utilization rate

Hawaii virus tracking

- New infections per mm, with % of positive cases
- Active hospitalizations per mm

Reopening

3% 3% 2% 0% 0% 0% 0% 0% 1% 1% 2% 1%

<---New infections per mm, with % of positive cases

Active hospitalizations per mm

Hawaii virus tracking

Current hospitalizations and daily infections

Daily deaths

- New daily infections (LHS)
- Cur Hosp (LHS)
- Daily deaths (RHS)

Source: COVID Tracking Project, JPAM. 9/1/2020. 7 day avgs.

Hawaii virus tracking

Positive tests/total tests

Total daily tests (000's)

- Positive testing rate (LHS)
- Daily # of tests (RHS)

Source: COVID Tracking Project, JPAM. 9/1/2020. 7 day avgs.

Hawaii virus tracking

Hospital bed utilization rates

South Dakota virus tracking

**New infections per mm, with % of positive cases**

**Active hospitalizations per mm**

**Daily deaths per mm**

**Case fatality rate, infections lagged 18 days**

**Daily deaths as a % of current hospitalizations**

**Positive tests/total tests**

**Total daily tests (000's)**

**New daily infections per mm**

**% of doctor visits with COVID-like symptoms**

**Hospital bed utilization rate**

**ICU bed utilization rate**

**2018 hosp bed utilization rate**

**2018 ICU bed utilization rate**

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.
Wyoming virus tracking

- New infections per mm, with % of positive cases
- Active hospitalizations per mm

Reopening

4% 7% 3% 3% 9% 2% 2% 1% 2% -3% 6% 5% 7% 7% 5% 7% 4%

0 5 10 15 20 25 30 35 40

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Wyoming virus tracking

Current hospitalizations and daily infections

Cur Hosp (LHS)
Daily deaths (RHS)

Daily deaths as a % of current hospitalizations

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Wyoming virus tracking

Positive tests/total tests

Positive testing rate (LHS)
Daily # of tests (RHS)

Source: COVID Tracking Project, JPMAM. 9/1/2020. 7 day avgs.

Wyoming virus tracking

Hospital utilization rates

Hospital bed utilization rate
ICU bed utilization rate
2018 hosp bed utilization rate
2018 ICU bed utilization rate

IMPORTANT INFORMATION

The views, opinions and estimates expressed herein constitute Michael Cembalest’s judgment based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

The views contained herein are not to be taken as advice or a recommendation to buy or sell any investment in any jurisdiction, nor is it a commitment from J.P. Morgan or any of its subsidiaries to participate in any of the transactions mentioned herein. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions and current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of production. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Both past performance and yields are not reliable indicators of current and future results.

Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates.

For J.P. Morgan Asset Management Clients:
J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://am.jpmorgan.com/global/privacy.

ACCESSIBILITY

For U.S. only: If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.

This communication is issued by the following entities:

In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients’ use only, by local J.P. Morgan entities, as the case may be.; in Canada, for institutional clients’ use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à.r.l. In Asia Pacific (“APAC”), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong; JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number “Kanto Local Finance Bureau (Financial Instruments Firm) No. 330”); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919). For all other markets in APAC, to intended recipients only.

For J.P. Morgan Private Bank Clients:

ACCESSIBILITY

J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. Please direct any accessibility issues to the Private Bank Client Service Center at 1-866-265-1727.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION

In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPM and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Trèves, L-2633, Senningerberg, Luxembourg. R.C.S. Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorised and regulated in accordance with the law of 5th April 1993. In the United
JPMorgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A.—London Branch. Prior to Brexit,(Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A.—London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Detailed about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.—London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.

In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In Italy, this material is distributed by J.P. Morgan Bank Luxembourg S.A.—Milan Branch, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A.is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. – Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registe red with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. In France, this material is distributed by JPMorgan Chase Bank, N.A. (“JPMCB”), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchès Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPM is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPM), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPM is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPM in Australia is to “wholesale clients” only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It may contain references to dollar amounts which are not Australian dollars;

may contain financial information which is not prepared in accordance with Australian law or practices;

may not address risks associated with investment in foreign currency denominated investments; and

does not address Australian tax issues.
With respect to countries in **Latin America**, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission—CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.